OPRX:NASDAQOptimizeRx Corporation analysis
Data as of Sep 27, 2026 - not real-time
- Latest price
- $8.04
- Risk: high
- 9/10High risk
Summary
The moving-average structure behind OptimizeRx Corporation is neutral at $8.04, with no clear ordering between short and long averages. Across the trailing 30 sessions it lost 8.4%. With RSI at 59.7 the momentum picture is neutral, alongside a bullish MACD signal. Price has been bracketed by support at $6.86 and resistance at $8.59.
Multiples put this in undervalued territory: 32.2 times earnings against the sector's 30.5. The average analyst target implies 54.2% above today's level. Revenue is contracting at 29.8% on a 4.7% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 42.8%, a beta of 1.91 and a maximum drawdown of 79.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to buy, carrying 4/10 conviction.
Multiples put this in undervalued territory: 32.2 times earnings against the sector's 30.5. The average analyst target implies 54.2% above today's level. Revenue is contracting at 29.8% on a 4.7% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 42.8%, a beta of 1.91 and a maximum drawdown of 79.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to buy, carrying 4/10 conviction.
Top market events
- OptimizeRx NASDAQ:OPRX reported second-quarter fiscal 2026 revenue of $20.
- Despite a 30% revenue decline, OptimizeRx Corp OPRX reaffirms full-year guidance, driven by AI-powered product growth...
- - Q2 revenue totals $20.5 million- Q2 net loss and adjusted EBITDA of $ 0.7 million and $4.9 million, respectively-...
Market outlook
Short term
< 1 yearPositive
Model confidence4/104 out of 10
Key factors
- Trading above the 200-day average of 7.85
- MACD momentum is positive
- 30-day price change of -8.4%
Medium term
1–3 yearsPositive
Model confidence4/104 out of 10
Key factors
- P/E of 32.2 versus sector average of 30.5
- Trading above the 200-day average of 7.85
- Analyst targets imply +54.2% versus the current price
Long term
> 3 yearsPositive
Model confidence4/104 out of 10
Key factors
- P/E of 32.2 versus sector average of 30.5
- Analyst targets imply +54.2% versus the current price
- Revenue contracting at -29.8%
Key metrics
Financial health
Revenue Growth-29.80%
Profit Margin4.66%
P/E Ratio32.2
ROE3.67%
ROA4.22%
Debt/Equity14.86
P/B Ratio1.2
Op. Cash Flow$18.4M
Free Cash Flow$15.8M
Industry P/E30.5
Technical analysis
TrendNeutral
RSI59.7
Support$6.86
Resistance$8.59
MA 20$7.67
MA 50$7.35
MA 200$7.85
MACDBullish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Fair Value$10.28
Target Price$12.40
Upside/Downside54.23%
GradeUndervalued
TypeBlend
Risk assessment
Beta1.91
Volatility42.79%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.